PHGE Overview

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Wall Street analysts forecast PHGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHGE is26.00 USD with a low forecast of 26.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Biomx Inc revenue for the last quarter amounts to -7.20M USD, decreased -23.47

Biomx Inc. EPS for the last quarter amounts to -4386000.00 USD, decreased -30.38

Biomx Inc (PHGE) has 20 emplpoyees as of March 11 2026.

Today PHGE has the market capitalization of 11.95M USD.